Onward Medical N.V.

AGM Information • Apr 29, 2022

Convocation of the 2022 Annual General Meeting of Shareholders and Proposed Resolutions

EINDHOVEN, the Netherlands & LAUSANNE, Switzerland — April 29, 2022, 7:00 CET – ONWARD Medical N.V. (Euronext: ONWD) (the Company), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, today has convened the 2022 Annual General Meeting of Shareholders (AGM), including the resolutions to be submitted for adoption at the AGM, which will be held in Amsterdam, the Netherlands, on June 10, 2022.

The resolutions, proposed by the Board, to be submitted for adoption at the AGM, are as follows:

• Adoption of the Company's statutory annual accounts for the financial year ended December 31, 2021, prepared in accordance with International Financial Reporting Standards (IFRS-EU). The 2021 statutory accounts were filed with the Netherlands Authority for the Financial Markets (AFM) on April 26, 2022 and are posted on the Company's website in the Investors section (https://ir.onwd.com)/) and the AFM's website (www.afm.nl).
• Implementation of the compensation policy over the financial year 2021 (advisory non-binding voting item).
• Release from liability of the members of the Board with respect to the performance of their duties during the financial year 2021.
• Instruction to Ernst & Young Audit for the external audit of the Company's annual accounts for the financial year 2022.
• The appointment of Ms. Kristina Dziekan as non-executive director of the Board for a fouryear term expiring at the end of the 2026 AGM.
• The delegation to the Board of the authority to issue ordinary shares and to grant rights to subscribe for such shares and to exclude pre-emption rights in respect of any issue of ordinary shares or any granting of rights to subscribe for such shares.
• The authorization to the Board to acquire ordinary shares in the capital of the Company.

The record date for all shareholders to participate at the AGM will be May 13, 2022. The convening notice, the complete agenda and all relevant detailed information concerning the 2022 AGM, as well as all related AGM materials, are available on the Company's website in the Investors section (https://ir.onwd.com)/) and made available to shareholders in compliance with legal requirements as of April 29, 2022.

To learn more about ONWARD's ARC Therapy and the company's vision to restore movement, independence and health in people with spinal cord injury, please visit ONWD.com.

About ONWARD

ONWARD is a medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury. ONWARD's work builds on more than a decade of basic science and preclinical research conducted at the world's leading neuroscience laboratories. ONWARD's ARC Therapy, which can be delivered by implantable (ARCIM) or external (ARCEX) systems, is designed to deliver targeted, programmed stimulation of the spinal cord to restore movement and other functions in people with spinal cord injury, ultimately improving their quality of life. ONWARD has received three Breakthrough Device Designations from the FDA encompassing both ARCIM and ARCEX. The company's first FDA pivotal trial, called Up-LIFT, completed enrollment in December 2021 with 65 subjects worldwide.

ONWARD is headquartered at the High Tech Campus in Eindhoven, the Netherlands. It maintains a significant team in Lausanne, Switzerland and has a growing U.S. presence in Boston, Massachusetts, USA. For additional information about the company, please visit ONWD.com. To access our 2022 Financial Calendar, please visit IR.ONWD.com.

For Media Enquiries: media@onwd.com +44 (0) 7884 496 251

For Investor Enquiries: investors@onwd.com

For Company Enquiries: ONWARD – info@onwd.com

The Company is listed on Euronext Brussels and Euronext Amsterdam as of 21 October 2021 under the ONWD ticker with international securities identification number NL0015000HT4.

Disclaimer

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors' current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking

statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.